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A r t i c l e s
Autoimmune diseases, such as multiple sclerosis, psoriasis, rheumatoid arthritis and type 1 diabetes, are the third ranked cause of human morbidity and mortality in the United States 1 . In these disorders, a failure in immune regulation results in T cell-mediated destruction of self tissues. The pathologic role of T cells in driving autoimmune diseases has resulted in numerous therapies aimed at inactivating T cells. The induction of long-term, durable antigen-specific T-cell tolerance is the ideal therapy, but published 'tolerance-inducing' strategies such as T cell epitope-specific peptides, T cell-specific antibodies or co-stimulation blockade [2] [3] [4] have not faired well clinically [5] [6] [7] [8] . Each failure was caused by issues associated specifically with the particular target and agent; however, many also involved concerns about safety and marginal efficacy. For example, cytokine release syndrome has been a common issue with the use of monoclonal antibody-based treatments, whereas soluble peptide infusion has induced anaphylactic responses in mouse models 9 .
We previously reported that intravenous administration of soluble peptides crosslinked to syngeneic splenic leukocytes using ethylene carbodiimide (ECDI) safely and efficiently induces antigen-specific immune tolerance, is effective in the prevention and treatment of T helper type 1 (T H 1) cell-and/or T H 17 cell-mediated autoimmune diseases and overcomes many of the drawbacks of the failed trials involving monoclonal antibodies and soluble peptides [10] [11] [12] . This strategy has recently been proven safe in a phase 1 clinical trial in patients with multiple sclerosis (S.D.M., unpublished data). However, the challenge of isolating isologous leukocytes and peptide coupling under good manufacturing practices (GMP) may inhibit clinical application of this therapy. The mechanism underpinning the beneficial effect of this strategy involves the delivery of an antigen in the context of apoptotic carrier cells 11, 12 . Therefore, we sought to achieve similar results using inert microparticles (500-nm diameter) instead of apoptotic cells. Microparticles do not have the stability, manufacturing, storage and other issues that complicate clinical translation of apoptotic cell-based therapies. A number of microparticle-based approaches designed to delay the release of small-molecule therapeutics have recently been approved by the US Food and Drug Administration 13 . Microparticles have also been used as adjuvants 14 .
Here we show that microparticles coupled to encephalitogenic myelin epitopes prevent and treat the clinical symptoms of experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. This treatment reduces inflammatory cell infiltration into and damage of the central nervous system (CNS). The beneficial effect of the microparticles requires the scavenger receptor MARCO, as mice deficient in MARCO are resistant to tolerance induced by antigen-linked microparticles but not by soluble peptide or antigen-coupled apoptotic cells. Furthermore, tolerance induced by peptide-coupled microparticles depends on both the induction of T-cell anergy and the activity of regulatory T (T reg ) cells.
Microparticles bearing encephalitogenic peptides induce t-cell tolerance and ameliorate experimental autoimmune encephalomyelitis RESULTS Antigen-linked polystyrene beads prevent and treat EAE The removal of apoptotic debris normally occurs without immune activation 15 . We have previously shown that intravenously (i.v.) administered apoptotic cells localize to the splenic marginal zone, where they mediate changes in scavenger receptor expression and upregulate interleukin-10 (IL-10) production 12 . Antigen-coupled apoptotic cell tolerance requires upregulation IL-10 production by macrophages, induction of Treg cells and co-inhibition of T cells through the CTLA-4 and PD-1 pathways 12, [16] [17] [18] . It is therefore crucial to identify a particle carrier that localizes to similar areas of the spleen and does not trigger immune activation pathways. We postulated that peptide-coupled syngeneic splenic leukocytes (antigen-splenocyte, Ag-SP) could be replaced by inert microparticles covalently linked with antigen.
We thus tested the ability of carboxylated 500-nm polystyrene beads (PSB) coupled with the immunodominant myelin proteolipid protein PLP 139-151 epitope (PLP 139-151 -PSB) to induce tolerance for the prevention and treatment of relapsing-remitting EAE (R-EAE). In this mouse model of relapsing-remitting multiple sclerosis, SJL/J mice are injected with PLP 139-151 in adjuvant initiating an autoreactive PLP-specific CD4 + T-cell response leading to the primary disease phase characterized by hindlimb paralysis. Mice then spontaneously remit from acute disease, although the tissue damage resulting from the primary response promotes the activation of T cells targeting a second PLP epitope, PLP [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] . This phenomenon is termed 'epitope spreading' and subsequently causes a second round (relapse) of hindlimb paralysis. In the same way, if mice are initially injected with PLP [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] (the subdominant epitope), PLP 139-151 will function as the spread epitope. Injection of PLP 139-151 -SP or PLP 139-151 -PSB, but not PSB coupled with an irrelevant ovalbumin peptide (OVA 323-339 ), 7 d before the initiation of disease protected the mice from disease (Fig. 1a) . Treatment with PLP 139-151 -PSB at the first sign of symptoms 
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A r t i c l e s (11 d after induction of disease) also prevented disease initiation in the vast majority of mice (Fig. 1b) , and this effect lasted for at least 66 d (Fig. 1c) . Although injection of PLP 139-151 -PSB 7 d before injection of PLP 178-191 mixed with complete Freund's adjuvant (CFA) did not prevent acute disease, indicating the antigen specificity of the tolerance, it did prevent relapse ( Fig. 1d) , indicating that this treatment could prevent epitope spreading. Treatment with PLP peptide-coupled PSB affected T-cell function. For example, we showed inactivation of myelin-specific CD4 + T cells by a lack of delayed-type hypersensitivity (DTH) responses, an in vivo measure of CD4 + T-cell function, to both the immunizing (PLP 139-151 ) and spread epitope (PLP 178-191 ) (Fig. 1e,f) 10 . Treatment with PLP 139-151 -PSB also reduced leukocyte (CD45 + ) and CD4 + T-cell infiltration of the CNS (Fig. 1g,h ). In addition, similarly to Ag-SP, Ag-PSB did not result in anaphylactic responses in mice with established disease unlike administration of soluble peptides 9 .
We next addressed the importance of covalent peptide linkage, microparticle size and route of administration. Covalent linkage with ECDI was essential, as PSB incubated with PLP 139-151 in the absence of ECDI had no impact on disease (Fig. 1i) . Normalizing for peptide mass (with each dose containing 20 µg of peptide), we coupled PLP 139-151 to particles with varying diameters (Fig. 1j) . Although 4.5-µm and 1.75-µm diameter particles provided some disease modification, optimal disease protection was conferred by treatment with the standard 500-nm PLP 139-151 -PSB, whereas 100-nm PLP 139-151 -PSB prevented relapse but did not confer any protection during acute disease. In addition, similarly to Ag-SP 12 , intravenous but not subcutaneous administration of PLP 139-151 -PSB protected against PLP 139-151 -initiated disease ( Fig. 1k) and prevented in vitro antigen-specific T cell-recall responses (Fig. 1l) .
MARCO mediates tolerance induction
The influence of microparticle size and administration route suggests that interactions with phagocytic cells in the splenic marginal zone may be crucial for microparticle-induced tolerance. We previously showed that the infusion of apoptotic debris upregulates the expression of select scavenger receptors, such as MARCO, in the spleen 12 . Scavenger receptors comprise a set of structurally diverse proteins, expressed predominately by phagocytes, that are important in the clearance of modified lipid particles and polyanionic ligands of both host and pathogen origin 19 . MARCO contributes to the uptake and clearance of particulate debris 20, 21 . We found that fluorescein isothiocyanate (FITC)-labeled PLP 139-151 -PSB administered i.v. localized with MARCO + cells in the splenic marginal zone, presumably the highly phagocytic marginal zone macrophages (MZMs) (Fig. 2) 22 . The cells containing FITC-labeled PLP 139-151 -PSB also expressed SIGN-R1, the murine homolog of DC-SIGN (Fig. 2b,e) that is expressed by MZMs with professional antigen-presenting capabilities 23, 24 , but they did not express SIGLEC-1, a marker that defines metallophilic macrophages (Fig. 2c,f) . Overall, the data indicate that PLP 139-151 -PSB administered i.v. localizes to MARCO + MZMs.
We confirmed the importance of MARCO in peptide-coupled particle tolerance using MARCO-deficient (Marco −/− ) BALB/c mice. Specifically, OVA 323-339 -PSB administered i.v. resulted in a decreased DTH response to subcutaneously (s.c.) injected OVA 323-339 and CFA in wild-type (WT) but not Marco −/− BALB/c mice (Fig. 2g) A role for MARCO in T-cell tolerance has not previously been defined. Thus, we further examined whether Marco −/− mice were resistant to other forms of tolerance induction. Similarly to WT mice, Marco −/− mice could be tolerized by infusion of soluble OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] (Fig. 2h) or OVA 323-339 -SP (Fig. 2i) . Cumulatively, the data show the importance of MARCO in T-cell tolerance induced by Ag-PSB. However, these findings indicate that soluble peptides and apoptotic Ag-SP induce tolerance through different mechanisms that probably involve different antigen uptake receptors.
T-cell extravasation
We next determined the temporal and kinetic effects of Ag-PSB infusion on circulating T cells using DO11.10 OVA 323-339 -specific T-cell receptor (TCR) transgenic mice and beads coupled to OVA 323-339 . We selected DO11.10 mice for this study to eliminate potential variables related to diverse TCR repertoires and/or the potential for self reactivity. OVA 323-339 -PSB administered i.v. triggered a rapid and sustained decrease in the number of OVA 323-339 -specific CD4 + T cells in the peripheral blood commensurate with a slight increase in the number of T cells in the spleen and lymph nodes ( Fig. 3a and  Supplementary Fig. 1 ). This reduction was antigen specific, as it was not induced by intravenous administration of myelin basic protein (MBP) 84-99 -PSB (Fig. 3a) . In addition, T cells in the blood and secondary lymphoid organs of these mice showed functional differences. T cells isolated from the lymph nodes, but not from the blood, of DO11.10 mice that had been i.v. injected with OVA 323-339 -PSB were hypoproliferative in response to OVA 323-339 stimulation (Fig. 3b,c) . These data imply that T-cell tolerance may require T-cell interaction with some cell populations located in the secondary lymphoid organs. 
Role of T reg cells and IL-10
We have previously shown that the T-cell tolerance induced by intravenous administration of peptides crosslinked to splenic leukocytes was partially dependent on IL-10 and the activity of antigenspecific CD4 + CD25 + Foxp3 + T reg cells 12 . Neutralization of IL-10 at the time of PLP 139-151 -PSB infusion had only a marginal effect on tolerance induction (Fig. 3d) . However, functional inactivation of T reg cells by treatment with the CD25-specific antibody PC61 (ref. 25) before PLP 139-151 -PSB infusion resulted in a modest but significant (P < 0.05, analysis of variance (ANOVA)) and reproducible reversal of the amount of protection during acute disease (Fig. 3e) . These results suggest that regulatory T cells have an important, but redundant, role in PSB-induced tolerance, as treatment with CD25-specific antibodies only partially blocked tolerance induction. IL-10 seems to make only modest contributions to PSB-induced tolerance.
T-cell abortive activation and anergy
To further explore the effects of these microparticles on T-cell proliferation and differentiation, we adoptively transferred carboxyfluorescein diacetate succinimidyl diester (CFSE)-labeled PLP 139-151 -specific transgenic (5B6) T cells into naive SJL/J mice. Forty-eight hours later, we i.v. injected 9 × 10 9 PLP 139-151 -PSB or OVA 323-339 -PSB or s.c. injected PLP 139-151 along with CFA. PLP 139-151 -specific T cells isolated from the spleen and lymph nodes of PLP 139-151 -PSB-treated mice showed markedly reduced proliferation (CFSE dilution) in terms of both the percentage of total cells divided and the number of divisions per cell compared to cells from mice injected with PLP 139-151 plus CFA (Fig. 4ai-iv) . Notably, this effect was antigen specific, as T cells from mice injected with OVA 323-339 -PSB did not show any CFSE dilution (Fig. 4av-vi) . We injected a subset of mice first i. (Fig. 4a,b) . The muted proliferation induced by peptide-coupled particle infusion suggests that tolerance may be induced by abortive T-cell activation. After adoptive transfer into naive SJL/J mice, PLP 139-151 -specific T cells isolated from mice injected i.v. with PLP 139-151 -PSB showed classical T-cell activation phenotypes: upregulated expression of CD69 and CD44 and downregulated expression of CD62L (Fig. 5a,b) . Notably, a larger fraction of splenic PLP 139-151 -specific T cells expressed CD69 in mice injected i.v. with PLP 139-151 -PSB than in mice injected s.c. with PLP 139-151 plus CFA (Fig. 5a) . However, the opposite was true with regard to CD44 expression (Fig. 5b) . In addition, T cells in mice i.v. administered PLP 139-151 -PSB produced neither interferon-γ (IFN-γ) nor IL-17, whereas cells in mice injected s.c. with PLP 139-151 and CFA produced both of these cytokines (Fig. 5c,d) . Furthermore, T cells from mice injected i.v. with PLP 139-151 -PSB produced minimal IL-17 and IFN-γ, even when the recipient mice were challenged s.c. with PLP 139-151 plus CFA 5 d later (Fig. 5c,d) ; as shown by OVA 323-339 injection, this effect was antigen specific. Together these findings suggest that PLP 139-151 -PSB induce abortive T-cell activation. A r t i c l e s by the addition of exogenous IL-2 to the cultures. (Fig. 6a-c) . Thus, antigenic peptides coupled to microparticles are capable of inducing T-cell anergy, which can be overcome in vitro through the addition of exogenous IL-2 (ref. 26 ).
Biodegradable microparticles induce T-cell tolerance
Our data highlight the ability of polystyrene microparticles to serve as antigen carriers to induce T-cell tolerance. To determine whether T-cell tolerance can also be induced with biocompatible, biodegradable microparticles, we tested particles made of the US Food and Drug Administration-approved material poly(lactide-co-glycolide) (PLG). PLG is stable and considered to be immunologically inert 13 . Similarly to PLP 139-151 -PSB, PLP 139-151 -PLG administered i.v. localized to the splenic marginal zone (Fig. 6d,e) . When administered prophylactically, PLP 139-151 -PLG administered i.v. reduced EAE clinical scores and PLP-specific DTH responses (Fig. 6f-h ). We were also able to treat ongoing EAE disease with i.v. administration of PLP 139-151 -PLG. (Fig. 6i) .
We then tested whether microparticles coupled with the appropriate relapse-associated myelin epitopes could inhibit disease relapse when administered during disease remission. Intravenous administration of PLP 178-191 -PLG 25 d after s.c. injection of PLP 139-151 and CFA reduced the severity of relapse symptoms (Fig. 6j) , as did infusion of PLP 139-151 -PLG 18 d after s.c. injection of PLP [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] and CFA (Fig. 6k) .
DISCUSSION
We found previously that antigenic peptides coupled to splenic leukocytes can be used as treatments in preclinical models of autoimmune disease, allergy and transplantation 12, 18, 27, 28 . This technique is currently being evaluated in the clinic for treatment of multiple sclerosis (S.D.M., unpublished data). However, the complexity and cost of producing antigen-coupled cells under GMP conditions may impede clinical translation. We undertook the current study to determine whether inert microparticles could be used as surrogates for apoptotic leukocytes as antigen 'carriers' . Inert microparticles coupled to peptides, unlike Ag-SP, can be produced in large amounts under GMP conditions. We demonstrate that both polystyrene and biodegradable PLG microparticles are highly efficient substitutes for apoptotic cells, as they are taken up in a MARCO scavenger receptor-dependent fashion and are capable of inducing long-term antigen-specific T-cell abortive activation and anergy.
To avoid complications of immunosuppression, the ability to tolerize T cells specific for autoantigens and alloantigens remains the desired treatment for a myriad of immune-mediated diseases. However, the translatability of the tolerance approaches demonstrated to be efficacious in animal studies has been lacking. Intravenous administration of anti-CD3 to induce tolerance in type 1 diabetes has resulted in questionable efficacy and safety concerns 29 . Attempts to potentially overcome some of these barriers through oral administration are under way, and some positive data have been obtained in small study involving 15 patients 30 . Initial studies using anti-CD3 to treat type 1 diabetes also showed similar positive outcomes 29 ; therefore, larger patient studies will be needed to clearly define any clinical benefit of oral over intravenous anti-CD3 treatment.
A number of antigen-specific approaches to generate tolerance have previously been tested in autoimmune diseases. Intradermal administration of CGP77116, an altered peptide ligand of MBP 83-99 , worsened symptoms in three patients with multiple sclerosis because in at least two of the patients there were 6 increased immune responses to MBP 83-99 . Attempts to induce 'high-zone tolerance' 31 by i.v. (MBP8298) infusion of a large bolus of peptide recently failed a phase 3 clinical trial in patients with multiple sclerosis 32 . Similarly, in type 1 diabetes, s.c. injection of the 65-kDa isoform of glutamic acid decarboxylase in alum had no effect on disease progression 33 . Mucosal antigen delivery has also shown promise in animal models of multiple sclerosis and type 1 diabetes 34 , but larger clinical trials testing oral and nasal administration of insulin have been ineffective in the prevention or reversal of new-onset type 1 diabetes 35, 36 .
Two DNA vaccines are also in development for treating patients with multiple sclerosis. BHT3009 encodes full-length MBP. In a phase 2 study, BHT3009 was administered at weeks 0, 2 and 4 and then monthly by s.c. injection. Although this treatment did not alter the relative risk for relapse or first time to relapse, there was a reduction in new CNS lesions 37 . The reduction in lesion formation was most prominent in patients that had high concentrations of antibodies targeting MBP, whereas patients with low anti-MBP titers had a similar rate of lesion formation as placebo-treated controls. Although further studies are needed to confirm the potential utility of BHT3009, the existence of a patient population that may not be responsive to BHT3009 supports the need for other therapeutic modalities.
A second DNA vaccine, ATX-MS-1467, expresses peptides that are thought to mimic processed myelin antigens and therefore act similarly to glatiramer acetate (GLAT), a random-length polymer of four amino acids (glutamic acid, lysine, alanine and tyrosine) found in MBP, which has been shown to compete with myelin peptides for access to the peptide binding cleft in the MHC complex 38 , promote T H 2 cell responses and induce IL-10-producing T reg cells 39 . These effects are not antigen specific, and as such, it may be predicted that the efficacy of ATX-MS-1467 may be similar to that of GLAT, resulting in a 50% reduction in multiple sclerosis relapses in responsive patients 38 .
Our data showing the requirement for peptides to be covalently linked to 500-nm particles and confirming the importance of i.v. administration for efficient tolerance induction 12 reinforce the importance of delivering the antigen-linked particles to the splenic marginal zone. As a possible explanation of the particle size requirement, it has been reported that compared to 20-nm diameter particles, 200-nm and 1,000-nm diameter particles have a higher propensity to bind to MARCO in vitro 40 . We show that MARCO-expressing MZM, but not SIGLEC-1-expressing metallophilic macrophages, take up peptide-linked particles. To our knowledge, MARCO has not previously been ascribed a role in T-cell tolerance, although this receptor was previously implicated in the pathogenesis of systemic lupus erythematosus; in systemic lupus erythematosus, it is postulated that failure of MARCO to remove apoptotic debris has a potential role in autoantibody formation 41, 42 . MARCO is also important for the uptake of bacteria 43 , silica particles 44 and polymer-based microparticles 40 . We speculate that MARCO functions through its ability to take up antigen-linked particles and assist in macrophage antigen presentation and/or antigen transfer to local dendritic cells. MARCO may also inhibit inflammatory responses by preventing dendritic cell migration 45 or by other unknown anti-inflammatory mechanisms 46 . However, although macrophage production of IL-10 is thought to be crucial for tolerance to apoptotic cells 12 , IL-10 neutralization failed to completely inhibit the tolerance induced by antigenic peptides coupled to microparticles. In addition, it seems that the MARCO pathway of tolerance induction is limited to microparticle-bound peptide, as Marco −/− mice were effectively tolerized to soluble peptide and peptides coupled to apoptotic splenic leukocytes.
PLP 139-151 -PSB infusion triggered antigen-specific T-cell extravasation into the lymphoid compartment. This extravasation was notable, as T cells isolated from the peripheral blood but not the lymph nodes within 48 h after treatment remained highly reactive to self antigen. This is probably the result of the inability of T cells to interact with tolerogenic antigen-presenting cells and/or T reg cells while in the laminar flow of the blood. In addition, PLP 139-151 -PSB infusion resulted in suboptimal PLP 139-151 -specific T-cell proliferation, cytokine production and activation in general. T-cell anergy was also induced, as nonresponsiveness could be largely reversed through the addition of exogenous IL-2 (refs. 26, 47) . Functional inactivation of T reg cells partially prevented the tolerance induced by antigenic peptide-coupled microparticles, which is in line with our previous studies using splenic leukocytes 12 . Upregulation of PD-L1 expression on splenic macrophages was implicated in our previous work, but we found only slight upregulation of PD-L1 expression on macrophages in mice treated with antigenic peptides coupled to microparticles (data not shown). Future experiments are required to further delineate the role of PD-L1 and CTLA-4 in antigen-coupled particle tolerance 17 .
Clinical translation of tolerance-based therapies for the treatment of autoimmune disease requires the ability to suppress pre-existing autoreactive effector T cells and/or establish tolerance of naive autoreactive T cells that may be activated after exposure to endogenous autoantigens released from damaged target organs (epitope spreading) 10 . Here we show that i.v. administration of PLP 139-151 -PSB can prophylactically prevent R-EAE, inhibit established R-EAE and suppress relapse caused by epitope spreading.
This study supports the use of antigen-coupled microparticles as a tool for tolerance induction. This option will probably have broad therapeutic utility, with preliminary studies in airway allergy 27 and allotolerance 18, 28 yielding promising results. From a clinical development perspective, identification of specific autoantigens and T-cell epitopes to be targeted in various autoimmune diseases, and a determination of the roles of scavenger receptors in various diseases, remain challenges for further investigations.
METhODS
Methods and any associated references are available in the online version of the paper.
